Busy day for Biohaven, with proposed buy of Channel Biosciences and BMS deal

26 February 2022

US neuroscience drug developer Biohaven Pharmaceutical (NYSE: BHVN) on Friday announced that it has entered into a definitive agreement to acquire Channel Biosciences, a subsidiary of Knopp Biosciences, and its Kv7 channel targeting platform – adding the latest advances in ion-channel modulation to Biohaven's growing neuroscience portfolio.

The Kv7 platform has been developed and refined for over a decade by a team with deep experience in ion channel science led by Dr Michael Bozik, and Steven Dworetzky. Both leaders, along with members of their scientific team, are anticipated to join Biohaven as part of the transaction, further bolstering the discovery and translational expertise at Biohaven Labs.

Financial terms include $100 million upfront, with over $1 billion contingent

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK